

In re Application of:
Pandian et al.
Application No.: 09/940,296
Filed: August 27, 2001
Page 3

PATENT
Attorney Docket No.: MBM1270

B. In the Claims

Applicant requests that the subject application be revised by amending claim 1 and canceling claims 25 to 29 as indicated below. Upon entry of the present amendment, the status of the claims will be as follows:

1. (Currently Amended) An amplification probe adapted to permit enhanced detectable labelling of a selected nucleic acid target, such probe comprising at least two regions of nucleic acid sequences: a first region including a homopolymeric sequence complementary to a sequence on a selected primary probe [which] wherein said primary probe also contains a sequence complementary to a sequence of said selected nucleic acid target, and a second region including more than two discretely labellable sequence units of more than one type.
2. (Previously Presented) An amplification probe as claimed in Claim 1, wherein the number of discretely labelable sequence units ranges from three to fifty in number.
3. (Original) An amplification probe as claimed in Claim 1, wherein each said discretely labelable sequence unit comprises a sequence of nucleotide bases hybridizable to a complementary sequence on a labelling probe, said labelling probe covalently attached to a detectable chemical label.
4. (Original) An amplification probe as claimed in Claim 3, wherein the length of each sequence unit ranges from 16 to 100 nucleotides.

In re Application of:
Pandian et al.
Application No.: 09/940,296
Filed: August 27, 2001
Page 4

PATENT
Attorney Docket No.: MBM1270

5. (Withdrawn) A method for enhancing detectable labeling of probe-target complexes in nucleic acid hybridization assays incorporating an amplification probe adapted to permit enhanced detectable labeling of a selected nucleic acid target, such probe comprising at least two regions of nucleic acid sequences: a first region including a sequence complementary to a sequence on a selected primary probe which also contains a sequence complementary to a sequence of said selected nucleic acid target, and a second region including a plurality of discretely labelable sequence units.

6. (Withdrawn) A method as claimed in Claim 5 wherein each said discretely labelable sequence unit comprises a sequence of nucleotide bases hybridizable to a complementary sequence on a labeling probe, said labeling probe covalently attached to a detectable chemical label.

7. (Withdrawn) A method as claimed in Claim 6 wherein the detectable chemical label is selected from an enzymatically active group, a fluorescer, a chromophore, a luminescer, a specifically bindable ligand, or a radioisotope.

8. (Withdrawn) A method as claimed in Claim 5 wherein a label attached to each said discretely labelable sequence units interacts with a reagent member of a label detection system to provide the detectable response.

9. (Withdrawn) The method as claimed in Claim 8 wherein the detectable chemical label is a substrate, cofactor, or inhibitor of an enzyme which is the member of the label detection system with which the label interacts to provide the detectable response.

In re Application of:
Pandian et al.
Application No.: 09/940,296
Filed: August 27, 2001
Page 5

PATENT
Attorney Docket No.: MBM1270

10. (Withdrawn) The method as claimed in Claim 9 wherein the label is a substrate which is acted on by the enzyme to produce a colorimetric, fluorescent or luminescent signal.

11. (Withdrawn) The method as claimed in Claim 9 wherein the label is a prosthetic group of an enzyme and wherein the apoenzyme of such enzyme is the member of the label detection system with which the label interacts to produce the catalytically active holoenzyme.

12. (Withdrawn) The method as claimed in Claim 11 wherein the prosthetic group is FAD and the apoenzyme is apo (glucose oxidase).

13. (Withdrawn) A method for detecting specific nucleic acid sequences comprising:

- a) hybridizing a first sequence of a primary polynucleotide probe to a selectable target nucleic acid sequence wherein the primary probe has a means for binding to an amplification probe comprising a nucleic acid sequence adapted to permit enhanced detectable labeling, the amplification probe being capable of hybridizing to at least one labeling probe comprising a nucleic acid sequence conjugated to a chemical label;
- b) immobilizing the target-probe complex;
- c) exposing the immobilized target-probe complex to said amplification probe, such probe comprising at least two regions of nucleic acid sequences: a first region including a sequence complementary to a sequence on a selected primary probe which also contains a sequence complementary to a sequence of said selected nucleic acid target, and a second region including a plurality of discretely labelable sequence units, under conditions that allows the amplification probe to hybridize to the target-probe complex;
- d) exposing the hybridized amplification probe to a labeling probe covalently attached to a detectable chemical label, such probe comprising sequences complementary to sequences on the amplification probe, under conditions that allows many labeling probes to hybridize to the amplification probe;
- e) observing the presence or absence of the detectable chemical label, covalently attached to said labeling probe, in association with the sample as indicating the presence or absence of the target sequence.

14. (Withdrawn) A method as claimed in Claim 13 wherein the means for immobilizing the probe-target complex involves an antibody reagent capable of binding to DNA/DNA, DNA/RNA or RNA/RNA duplexes formed between the selectable target sequence and the complementary primary probe sequence.

15. (Withdrawn) A method as claimed in Claim 14 wherein the antibody reagent is:

- (i) selective for binding DNA/RNA hybrids wherein one of the probe and the sequence to be detected is DNA and the other is RNA,
- (ii) selective for binding RNA/RNA hybrids wherein both the probe and the sequence to be detected are RNA, or
- (iii) selective for binding intercalation complexes wherein the duplexes formed in the assay comprise a nucleic acid intercalator bound thereto in the form of intercalation complexes.

16. (Withdrawn) A method as claimed in Claim 13 wherein the detectable chemical label is selected from an enzymatically active group, a fluorescer, a chromophore, a luminescer, a specifically bindable ligand, or a radioisotope.

17. (Withdrawn) A method as claimed in Claim 13 wherein a label attached to each said discretely labelable sequence units interacts with a reagent member of a label detection system to provide the detectable response.

18. (Withdrawn) The method as claimed in Claim 17 wherein the label is a substrate, cofactor, or inhibitor of an enzyme which is the member of the label detection system with which the label interacts to provide the detectable response.

19. (Withdrawn) The method as claimed in Claim 18 wherein the label is a substrate which is acted on by the enzyme to produce a colorimetric, fluorescent or luminescent signal.

20. (Withdrawn) The method as claimed in Claim 18 wherein the label is a prosthetic group of an enzyme and wherein the apoenzyme of such enzyme is the member of the label detection system with which the label interacts to produce the catalytically active holoenzyme.

21. (Withdrawn) The method as claimed in Claim 20 wherein the prosthetic group is FAD and the apoenzyme is apo (glucose oxidase).

22. (Withdrawn) A method as claimed in Claim 13 applied to the detection of a particular nucleic acid sequence in a test medium wherein the test medium comprises a biological sample which has been subjected to conditions to release and denature nucleic acids present therein.

23. (Withdrawn) A method as claimed in Claim 22 wherein the biological sample includes food substances and the target nucleic acid sequence is of a bacterial microorganism.

24. (Withdrawn) A method as claimed in Claim 22 wherein the biological sample includes food substances and the target nucleic acid sequence is of a virus.

Claims 25-29 (Cancelled).